Search results
Results from the WOW.Com Content Network
Xeris Biopharma (NASDAQ:XERS) stock is rallying after the drug maker announced that its Recorlev drug had been approved by the U.S. Food and Drug Administration for certain patients with Cushing ...
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the ...
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
For premium support please call: 800-290-4726 more ways to reach us
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
For premium support please call: 800-290-4726 more ways to reach us
The chipmaker's stock fell about 3% after China launched a probe into the company, investigating whether the ... Gen Xers are struggling to save for retirement as they take care of both their kids ...